|
1
|
Hanahan D and Folkman J: Patterns and
emerging mechanisms of the angiogenic switch during tumorigenesis.
Cell. 86:353–364. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Döme B, Hendrix MJ, Paku S, Tóvári J and
Tímár J: Alternative vascularization mechanisms in cancer:
Pathology and therapeutic implications. Am J Pathol. 170:1–15.
2007.PubMed/NCBI
|
|
3
|
Maniotis AJ, Folberg R, Hess A, et al:
Vascular channel formation by human melanoma cells in vivo and in
vitro: vasculogenic mimicry. Am J Pathol. 155:739–752. 1999.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Basu GD, Pathangey LB, Tinder TL, Gendler
SJ and Mukherjee P: Mechanisms underlying the growth inhibitory
effects of the cyclo-oxygenase-2 inhibitor celecoxib in human
breast cancer cells. Breast Cancer Res. 7:R422–R435. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
El Hallani S, Boisselier B, Peglion F, et
al: A new alternative mechanism in glioblastoma vascularization:
tubular vasculogenic mimicry. Brain. 133:973–982. 2010.PubMed/NCBI
|
|
6
|
Sharma N, Seftor RE, Seftor EA, et al:
Prostatic tumor cell plasticity involves cooperative interactions
of distinct phenotypic subpopulations: role in vasculogenic
mimicry. Prostate. 50:189–201. 2002. View Article : Google Scholar
|
|
7
|
Sun B, Zhang D, Zhang S, Zhang W, Guo H
and Zhao X: Hypoxia influences vasculogenic mimicry channel
formation and tumor invasion-related protein expression in
melanoma. Cancer Lett. 249:188–197. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Millimaggi D, Mari M, D’ Ascenzo S, Giusti
I, Pavan A and Dolo V: Vasculogenic mimicry of human ovarian cancer
cells: role of CD147. Int J Oncol. 35:1423–1428. 2009.PubMed/NCBI
|
|
9
|
Zhang S, Zhang D and Sun B: Vasculogenic
mimicry: current status and future prospects. Cancer Lett.
254:157–164. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Wang JY, Sun T, Zhao XL, et al: Functional
significance of VEGF-a in human ovarian carcinoma: role in
vasculogenic mimicry. Cancer Biol Ther. 7:758–766. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Liu R, Yang K, Meng C, Zhang Z and Xu Y:
Vasculogenic mimicry is a marker of poor prognosis in prostate
cancer. Cancer Biol Ther. 13:527–533. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Kota BP, Huang TH and Roufogalis BD: An
overview on biological mechanisms of PPARs. Pharmacol Res.
51:85–94. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Kim S, Lee JJ and Heo DS: PPARgamma
ligands induce growth inhibition and apoptosis through p63 and p73
in human ovarian cancer cells. Biochem Biophys Res Commun.
406:389–395. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Lyles BE, Akinyeke TO, Moss PE and Stewart
LV: Thiazolidinediones regulate expression of cell cycle proteins
in human prostate cancer cells via PPARgamma-dependent and
PPARgamma-independent pathways. Cell Cycle. 8:268–277. 2009.
View Article : Google Scholar
|
|
15
|
Fujita M, Yagami T, Fujio M, et al:
Cytotoxicity of troglitazone through PPARgamma-independent pathway
and p38 MAPK pathway in renal cell carcinoma. Cancer Lett.
312:219–227. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Kim KY, Ahn JH and Cheon HG:
Anti-angiogenic action of PPARgamma ligand in human umbilical vein
endothelial cells is mediated by PTEN upregulation and VEGFR-2
downregulation. Mol Cell Biochem. 358:375–385. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Panigrahy D, Singer S, Shen LQ, et al:
PPARgamma ligands inhibit primary tumor growth and metastasis by
inhibiting angiogenesis. J Clin Invest. 110:923–932. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Tian L, Zhou J, Casimiro MC, et al:
Activating peroxisome proliferator-activated receptor gamma mutant
promotes tumor growth in vivo by enhancing angiogenesis. Cancer
Res. 69:9236–9244. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Lissitzky JC, Parriaux D, Ristorcelli E,
Verine A, Lombardo D and Verrando P: Cyclic AMP signaling as a
mediator of vasculogenic mimicry in aggressive human melanoma cells
in vitro. Cancer Res. 69:802–809. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Liu H, Chen A, Guo F and Yuan L: A
short-hairpin RNA targeting osteopontin downregulates MMP-2 and
MMP-9 expressions in prostate cancer PC-3 cells. Cancer Lett.
295:27–37. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Yamashita D, Shimizu M and Osumi T:
Mechanism for the action of PPARs. Nihon Rinsho. 63:536–537.
2005.(In Japanese).
|
|
22
|
Shukla S, Maclennan GT, Hartman DJ, Fu P,
Resnick MI and Gupta S: Activation of PI3K-Akt signaling pathway
promotes prostate cancer cell invasion. Int J Cancer.
121:1424–1432. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Wang J, Wang J, Sun Y, Song W, Nor JE,
Wang CY and Taichman RS: Diverse signaling pathways through the
SDF-1/CXCR4 chemokine axis in prostate cancer cell lines leads to
altered patterns of cytokine secretion and angiogenesis. Cell
Signal. 17:1578–1592. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Jemal A, Bray F, Center MM, Ferlay J, Ward
E and Forman D: Global cancer statistics. CA Cancer J Clin.
61:69–90. 2011. View Article : Google Scholar
|
|
25
|
de Bono JS, Oudard S, Ozguroglu M, et al:
Prednisone plus cabazitaxel or mitoxantrone for metastatic
castration-resistant prostate cancer progressing after docetaxel
treatment: a randomised open-label trial. Lancet. 376:1147–1154.
2010.
|
|
26
|
Samaranayake H, Määttä AM, Pikkarainen J
and Ylä-Herttuala S: Future prospects and challenges of
antiangiogenic cancer gene therapy. Hum Gene Ther. 21:381–396.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
van der Schaft DW, Seftor RE, Seftor EA,
et al: Effects of angiogenesis inhibitors on vascular network
formation by human endothelial and melanoma cells. J Natl Cancer
Inst. 96:1473–1477. 2004.PubMed/NCBI
|
|
28
|
Pàez-Ribes M, Allen E, Hudock J, et al:
Antiangiogenic therapy elicits malignant progression of tumors to
increased local invasion and distant metastasis. Cancer Cell.
15:220–231. 2009.PubMed/NCBI
|
|
29
|
Qu B, Guo L, Ma J and Lv Y:
Antiangiogenesis therapy might have the unintended effect of
promoting tumor metastasis by increasing an alternative circulatory
system. Med Hypotheses. 74:360–361. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Xu Y, Li Q, Li XY, Yang QY, Xu WW and Liu
GL: Short-term anti-vascular endothelial growth factor treatment
elicits vasculogenic mimicry formation of tumors to accelerate
metastasis. J Exp Clin Cancer Res. 31:162012. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Itzhaki O, Greenberg E, Shalmon B, et al:
Nicotinamide inhibits vasculogenic mimicry, an alternative
vascularization pathway observed in highly aggressive melanoma.
PLoS One. 8:e571602013. View Article : Google Scholar
|
|
32
|
Fan YZ and Sun W: Molecular regulation of
vasculogenic mimicry in tumors and potential tumor-target therapy.
World J Gastrointest Surg. 2:117–127. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Goetze S, Eilers F, Bungenstock A, et al:
PPAR activators inhibit endothelial cell migration by targeting
Akt. Biochem Biophys Res Commun. 293:1431–1437. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Vartanian A, Stepanova E, Grigorieva I,
Solomko E, Baryshnikov A and Lichinitser M: VEGFR1 and PKCalpha
signaling control melanoma vasculogenic mimicry in a VEGFR2
kinase-independent manner. Melanoma Res. 21:91–98. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
van der Schaft DW, Hillen F, Pauwels P, et
al: Tumor cell plasticity in Ewing sarcoma, an alternative
circulatory system stimulated by hypoxia. Cancer Res.
65:11520–11528. 2005.PubMed/NCBI
|
|
36
|
Lirdprapamongkol K, Chiablaem K, Sila-Asna
M, Surarit R, Bunyaratvej A and Svasti J: Exploring stemness gene
expression and vasculogenic mimicry capacity in well- and
poorly-differentiated hepatocellular carcinoma cell lines. Biochem
Biophys Res Commun. 422:429–435. 2012. View Article : Google Scholar
|
|
37
|
Yoshizaki T, Motomura W, Tanno S, Kumei S,
Yoshizaki Y and Okumura T: Thiazolidinediones enhance vascular
endothelial growth factor expression and induce cell growth
inhibition in non-small-cell lung cancer cells. J Exp Clin Cancer
Res. 29:222010. View Article : Google Scholar
|
|
38
|
Hess AR, Seftor EA, Seftor RE and Hendrix
MJ: Phosphoinositide 3-kinase regulates membrane Type 1-matrix
metalloproteinase (MMP) and MMP-2 activity during melanoma cell
vasculogenic mimicry. Cancer Res. 63:4757–4762. 2003.PubMed/NCBI
|
|
39
|
Chetty C, Lakka SS, Bhoopathi P and Rao
JS: MMP-2 alters VEGF expression via alphaVbeta3 integrin-mediated
PI3K/AKT signaling in A549 lung cancer cells. Int J Cancer.
127:1081–1095. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Chen WC, Lin MS and Bai X: Induction of
apoptosis in colorectal cancer cells by peroxisome
proliferators-activated receptor gamma activation up-regulating
PTEN and inhibiting PI3K activity. Chin Med J (Engl).
118:1477–1481. 2005.PubMed/NCBI
|
|
41
|
Trisciuoglio D, Iervolino A, Zupi G and
Del Bufalo D: Involvement of PI3K and MAPK signaling in
bcl-2-induced vascular endothelial growth factor expression in
melanoma cells. Mol Biol Cell. 16:4153–4162. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Pore N, Gupta AK, Cerniglia GJ and Maity
A: HIV protease inhibitors decrease VEGF/HIF-1alpha expression and
angiogenesis in glioblastoma cells. Neoplasia. 8:889–895. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Zhong H, Chiles K, Feldser D, et al:
Modulation of hypoxia-inducible factor 1alpha expression by the
epidermal growth factor/phosphatidylinositol 3-kinase/PTEN/AKT/FRAP
pathway in human prostate cancer cells: implications for tumor
angiogenesis and therapeutics. Cancer Res. 60:1541–1545. 2000.
|
